Evidence map›Paper›PMID 40852696›Full record

ArticleInternational journal of hematology-oncology and stem cell research2025

Durable Remission after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Refractory Mycosis Fungoides: A Case Report.

Mekni Sabrine, Ben Hammamia Hana, Noureddine Litaiem, Kanoun Rimmel Yosra, Torjemane Lamia, Belloumi Dorra, Ben Yaiche Insaf, Ouerghi Rihab, Turki Ines, Chaabane Anna and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mekni SabrineFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Ben Hammamia HanaFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Noureddine LitaiemFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Kanoun Rimmel YosraFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Torjemane LamiaFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Belloumi DorraFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Ben Yaiche InsafFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Ouerghi RihabFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Turki InesFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Chaabane AnnaFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Ben Othman TarekFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.
Ben Abdeljelil NourFaculty of Medicine, University of Tunis El Manar, National Center of Stem cell Transplantation, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) and is characterized by a heterogeneous clinical course and variant stage involvement. Indolent disease is usually observed in its early stages. However, the treatment options for patients with advanced MF are limited and have poor outcomes. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for refractory cases. Here, we describe the case of a 34-year-old man who was diagnosed with MF at an advanced stage. Eight months before allo-HSCT, the patient received six courses of polychemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisolone, which were administered every three weeks. A partial response was obtained. He underwent allo-HSCT after a myeloablative conditioning regimen and remained in complete remission (CR) for 26 months posttransplantation. Our findings confirm that allo-HSCT can be a curative option for refractory MF

Indexed as

Allogeneic stem cell transplantationMycosis FungoidesRefractory

Identifiers

PMID40852696
PMCPMC12368711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.